Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sea Limited
SE
|
+$1.96B |
| 2 |
AbbVie
ABBV
|
+$1.42B |
| 3 |
D.R. Horton
DHI
|
+$783M |
| 4 |
Amazon
AMZN
|
+$603M |
| 5 |
Eli Lilly
LLY
|
+$586M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian Natural Resources
CNQ
|
+$1.18B |
| 2 |
EOG Resources
EOG
|
+$999M |
| 3 |
JPMorgan Chase
JPM
|
+$874M |
| 4 |
Comcast
CMCSA
|
+$746M |
| 5 |
TC Energy
TRP
|
+$626M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.11% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 13.72% |
| 4 | Industrials | 10.84% |
| 5 | Financials | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Affirm
AFRM
$24.7B
| $515M | 0.17% |
27,433,886
+2,642,358
| +11% | +$69.1M |
|
127
Arista Networks
ANET
$264B
| $509M | 0.17% |
18,024,016
+48,076
| +0.3% | +$1.39M |
|
128
Texas Instruments
TXN
$253B
| $499M | 0.16% |
3,226,583
+320,483
| +11% | +$53.7M |
|
129
Zoetis
ZTS
$30.2B
| $492M | 0.16% |
3,318,652
+686
| +0% | +$115K |
|
|
FRC
130
DELISTED
First Republic Bank
FRC
| $486M | 0.16% |
3,723,300
+947
| +0% | +$145K |
|
131
Williams-Sonoma
WSM
$28.6B
| $483M | 0.16% |
8,198,090
-1,067,042
| -12% | -$75.7M |
|
132
Entergy
ETR
$50.3B
| $477M | 0.16% |
9,483,732
+3,191,802
| +51% | +$183M |
|
133
Coca-Cola
KO
$375B
| $474M | 0.16% |
8,454,343
+67,039
| +0.8% | +$4.17M |
|
134
Halliburton
HAL
$27.6B
| $470M | 0.15% |
19,074,519
+1,064,671
| +6% | +$30.4M |
|
135
Wyndham Hotels & Resorts
WH
$5.5B
| $469M | 0.15% |
7,645,840
+1,120,426
| +17% | +$75M |
|
136
Haemonetics
HAE
$4.14B
| $465M | 0.15% |
6,286,276
+4,840
| +0.1% | +$348K |
|
137
Air Products & Chemicals
APD
$68B
| $458M | 0.15% |
1,968,693
+973,565
| +98% | +$241M |
|
138
S&P Global
SPGI
$122B
| $445M | 0.15% |
1,458,657
-53,182
| -4% | -$19M |
|
139
Qorvo
QRVO
$8.67B
| $445M | 0.15% |
5,605,661
+242,833
| +5% | +$23.5M |
|
140
Arch Capital
ACGL
$33.4B
| $442M | 0.15% |
9,697,564
-1,198
| -0% | -$54.1K |
|
|
DHR.PRB
141
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
| $439M | 0.14% |
325,856
+35,200
| +12% | +$50M |
|
|
OSH
142
DELISTED
Oak Street Health, Inc.
OSH
| $436M | 0.14% |
17,778,869
+3,905,081
| +28% | +$103M |
|
143
Americold
COLD
$4.23B
| $428M | 0.14% |
17,417,588
+1,096,046
| +7% | +$33.1M |
|
144
NVR
NVR
$16.8B
| $425M | 0.14% |
106,713
+16
| +0% | +$68.2K |
|
145
Prologis
PLD
$135B
| $421M | 0.14% |
4,139,769
+860,237
| +26% | +$107M |
|
146
BioMarin Pharmaceuticals
BMRN
$13.3B
| $418M | 0.14% |
4,936,740
+1,394
| +0% | +$124K |
|
147
HDFC Bank
HDB
$119B
| $412M | 0.14% |
14,102,330
-578,728
| -4% | -$17.8M |
|
|
BLD
148
DELISTED
TopBuild
BLD
| $411M | 0.13% |
2,491,209
+125,738
| +5% | +$23.2M |
|
149
CrowdStrike
CRWD
$229B
| $408M | 0.13% |
9,913,736
+9,204
| +0.1% | +$421K |
|
150
Otis Worldwide
OTIS
$28B
| $393M | 0.13% |
6,152,879
-233,637
| -4% | -$17.1M |
|
Similar funds
Capital Research Global Investors's Q3 2022 Portfolio in Review
As of Q3 2022, Capital Research Global Investors held 452 positions worth $304B, down 5.2% from $321B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Capital Research Global Investors's Q3 2022 filing shows 29 new, 189 increased, 162 reduced and 23 closed positions. Its largest new stake was Centene: 2,829,733 shares worth $220M. The largest sale was Canadian Natural Resources, an estimated $1.18B.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Capital Research Global Investors's largest Q3 2022 buy was Centene: 2,829,733 shares worth $220M.
- Capital Research Global Investors added most to Sea Limited in Q3 2022, an estimated $1.96B increase.
- Capital Research Global Investors's biggest Q3 2022 reduction was Canadian Natural Resources, cutting an estimated $1.18B.
- Capital Research Global Investors fully exited Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock, Series A in Q3 2022, selling an estimated $210M.
- Capital Research Global Investors's ten largest holdings make up 28% of its $304B portfolio in Q3 2022.
- Capital Research Global Investors opened 29 new positions and closed 23 in Q3 2022.
- Capital Research Global Investors's portfolio value fell 5.2% quarter-over-quarter to $304B.
Based on Capital Research Global Investors's 13F filing for Q3 2022, filed 14 Nov 2022.